Serum levels of insulin-like growth factor-1 and growth factor binding protein-3 in children with acute lymphocytic leukemia.
- Author:
Dong-Ju ZHAO
1
;
Wen-Lin ZHANG
;
Tai-Xin SHI
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Biomarkers, Tumor; blood; Child; Child, Preschool; Female; Humans; Infant; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Proteins; blood; Insulin-Like Growth Factor I; analysis; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; blood; diagnosis
- From: Chinese Journal of Contemporary Pediatrics 2011;13(2):101-103
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study serum levels and clinical significance of insulin-like growth factor-1 (IGF-1) and growth factor binding protein 3 (IGFBP-3) in children with acute lymphocytic leukemia (ALL).
METHODSSerum samples were obtained from 36 children with ALL before treatment and 6 months after complete remission. Thirty children with surgical diseases severed as the control group. Serum IGF-1 levels were measured using radioimmunoassay (RIA). Serum IGFBP-3 levels were measured using immunoradioassays (IRMA).
RESULTSSerum levels of IGF-1 and IGFBP-3 in the ALL group were 19±4 ng/mL and 1216±132 ng/mL, respectively before treatment, which were lower than those in the control group (32±3 ng/mL and 2104±191 ng/mL respectively) (P<0.01). Serum levels of IGF-1 and IGFBP-3 in the ALL group increased to 30±3 ng/mL and 1941±164 ng/mL respectively 6 months after complete remission, which were significantly higher than those before treatment (P<0.01) and were similar to the levels of the control group.
CONCLUSIONSSerum levels of IGF-1 and IGFBP-3 are reduced in children with ALL, but increase significantly after complete remission, suggesting that IGF-1 and IGFBP-3 might serve as useful markers for the diagnosis and evaluation of therapeutic effects of childhood ALL.